Hosts Luncheon Presentation for New York Investment Community
NEW YORK, New York/ WINNIPEG, Manitoba - (February 17, 2004). Medicure Inc. (TSX: MPH, Amex: MCU), a cardiovascular
drug discovery and development company, is pleased to announce that
the common shares of the Company began trading today on the American
Stock Exchange® (Amex®), under the ticker symbol MCU.
As part of the day's events, Medicure hosted a luncheon presentation
at the Waldorf=Astoria Hotel for 100 people from the New York financial
and business communities. The event featured presentations on the
Company and a review of ongoing clinical trials and future initiatives.
The presentation was attended by biotech analysts, retail brokers,
portfolio managers, investment bankers and private investors.
"Today was a very important day in the history of our Company,"
stated Albert D. Friesen, Ph.D., Medicure's President and Chief
Executive Officer. "We were delighted at the level of interest
and support that we received at today's presentation.
"This United States listing gives Medicure increased visibility
in the American marketplace and makes the Company significantly
more accessible to U.S. investors," he added.
In conjunction with the listing, Medicure selected Kellogg Capital
Group as its specialist.
Medicure also announced today that it has engaged the services
of Barry Kaplan Associates to assist the Company in its investor
relations initiatives in the United States.
The Company's common shares can now be traded on either the Toronto
Stock Exchange® or the American Stock Exchange®.
About Medicure Inc.
Medicure Inc. is a cardiovascular drug discovery and development
Company focused on developing effective therapeutics for unmet needs
in the field of cardiovascular medicine. The Company's lead drug,
MC-1, is focused on the prevention and treatment of ischemia, ischemic
reperfusion injury, and stroke. The cardiovascular and stroke market
is the largest pharmaceutical sector with annual global sales of
over US $70 billion.
The Company's second product candidate, MC-4232, is being targeted
for the treatment of hypertension, a common disorder in which blood
pressure remains abnormally high. Approximately 73% of the more
than 50 million adult Americans who have hypertension, are not adequately
treated.
Medicure also has a medicinal chemistry based Drug Discovery program
focused on discovery and advancement of novel small molecule, anti-ischemics
and anti-thrombotics towards human clinical studies.
This news release
contains forward-looking statements that involve risks, which may
cause actual results to differ materially from the statements made,
and accordingly may be deemed to be forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
made as of the date hereof, and the Company disclaims any intention
and has no obligation or responsibility to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
For more information, please contact:
Derek Reimer
Chief Financial Officer
Don Bain
Director of Investor & Public Relations
